Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Amortization - Intangibles (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Amortization - Intangibles for 11 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles fell 2.54% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.7 million through Dec 2025, down 0.91% year-over-year, with the annual reading at $32.7 million for FY2025, 0.91% down from the prior year.
  • Amortization - Intangibles hit $8.1 million in Q4 2025 for Ligand Pharmaceuticals, roughly flat from $8.1 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $11.8 million in Q3 2021 to a low of -$1.2 million in Q4 2021.
  • Historically, Amortization - Intangibles has averaged $8.4 million across 5 years, with a median of $8.3 million in 2023.
  • Biggest five-year swings in Amortization - Intangibles: tumbled 478.1% in 2021 and later skyrocketed 813.85% in 2022.
  • Year by year, Amortization - Intangibles stood at -$1.2 million in 2021, then surged by 813.85% to $8.5 million in 2022, then decreased by 1.93% to $8.3 million in 2023, then fell by 0.47% to $8.3 million in 2024, then decreased by 2.54% to $8.1 million in 2025.
  • Business Quant data shows Amortization - Intangibles for LGNDZ at $8.1 million in Q4 2025, $8.1 million in Q3 2025, and $8.3 million in Q2 2025.